Biogen hit with Italian antitrust probe over multiple sclerosis market
( May 27, 2026, 06:53 GMT | Official Statement) -- MLex Summary: US pharma company Biogen is the target of an Italian antitrust probe into alleged efforts to shield its blockbuster multiple-sclerosis treatment from biosimilar competition. Investigators say Biogen is refusing to allow patients using the biosimilar marketed by Sandoz access to a must-have test that the US company owns. The press release follows. An English translation of the decision opening proceedings is attached. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.